Short answer
Dexcom (DXCM) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.3B (up 11.2% year over year) with net income of $275M.
Q3 2026 key financials · XBRL
- Revenue
- $1.3B
- +11.2% YoY · +2.8% QoQ
- Net income
- $275M
- −3.1% YoY · +10.4% QoQ
- Operating margin
- 24.3%
- Gross margin
- 64.3%
- EPS (diluted)
- $0.72
- +1.4% YoY · +12.5% QoQ
Source: XBRL data from the Dexcom (DXCM) Q3 2026 10-Q on SEC EDGAR. USD.
Dexcom Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1,344.5M, up $135.2M or 11% YoY, driven by disposable sensor volume
- Gross margin 64.3% vs 60.5% YoY, supported by G7 15 Day and manufacturing efficiencies
- Operating income $327.2M, up 35% YoY; operating margin 24.3% vs 20.1%
- Cash $1.82B, down $180.8M from December 31, 2025; nine-month operating cash flow $1.12B
- Share repurchases drove $1,023.8M financing cash use; significant manufacturing capital expenditures expected next year
Risk Factors
- New shareholder-return risk: October 2026 authorization of $1.00 billion 2027 Share Repurchase Program
- Most material update: Repurchases may not enhance share price or earnings per share
- Market risk: Repurchase timing could expose Dexcom to unfavorable market conditions and price volatility
- Financial risk: Share buybacks depend on availability of funds and competing strategic opportunities
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Dexcom quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.